The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression

被引：1

作者：

Goodwin, Guy M. ^{[1
]}

Aaronson, Scott T. ^{[2
,3
]}

Alvarez, Oscar ^{[4
,5
]}

Carhart-Harris, Robin ^{[6
]}

Chai-Rees, Jamie ^{[1
]}

Croal, Megan ^{[1
]}

Debattista, Charles

Dunlop, Boadie W. ^{[7
]}

Feifel, David ^{[8
]}

Hellerstein, David J. ^{[9
]}

Husain, Muhammad I. ^{[10
,11
]}

Kelly, John R. ^{[12
]}

Kirlic, Namik ^{[13
]}

Licht, Rasmus W. ^{[14
,15
]}

Marwood, Lindsey ^{[1
]}

Meyer, Thomas D. ^{[16
]}

Mistry, Sunil ^{[1
]}

Nowakowska, Ania ^{[1
]}

Palenicek, Tomas ^{[17
]}

Repantis, Dimitris ^{[18
]}

Schoevers, Robert A. ^{[19
]}

Simmons, Hollie ^{[1
]}

Somers, Metten ^{[20
]}

Teoh, Emma ^{[1
]}

Tsai, Joyce ^{[13
]}

Wahba, Mourad ^{[21
,22
]}

Williams, Sam ^{[1
]}

Young, Allan H. ^{[23
,24
]}

Young, Matthew B. ^{[13
]}

Zisook, Sidney ^{[25
]}

Malievskaia, Ekaterina ^{[1
]}

机构：

[1] COMPASS Pathfinder Ltd, London, England

[2] Sheppard Pratt, Inst Adv Diagnost & Therapeut, Baltimore, MD USA

[3] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD USA

[4] Parc Sanitari St Joan de Deu, Barcelona, Spain

[5] St Joan de Deu Res Fdn, Barcelona, Spain

[6] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA USA

[7] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA

[8] Kadima Neuropsychiat Inst, San Diego, CA USA

[9] Columbia Univ, New York State Psychiat Inst, Vagelos Coll Phys & Surg, Dept Psychiat, New York, NY USA

[10] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada

[11] Univ Toronto, Temerty Fac Med, Dept Psychiat, Toronto, ON, Canada

[12] Tallaght Univ Hosp, Trinity Ctr Hlth Sci, Dept Psychiat, Dublin, Ireland

[13] COMPASS Pathways, New York, NY USA

[14] Aalborg Univ Hosp, Dept Psychiat, Aalborg, Denmark

[15] Aalborg Univ, Dept Clin Med, Aalborg, Denmark

[16] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Faillace Dept Psychiat & Behav Sci, Houston, TX USA

[17] Natl Inst Mental Hlth, Klecany, Czech Republic

[18] Charite, Dept Psychiat & Neurosci, Univ Med Berlin, Berlin, Germany

[19] Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands

[20] Univ Med Ctr Utrecht, Brain Ctr, Dept Psychiat, Utrecht, Netherlands

[21] Cumbria Northumberland Tyne & Wear NHS Fdn Trust, Morpeth, England

[22] Newcastle Univ, Newcastle Upon Tyne, England

[23] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England

[24] South London & Maudsley NHS Fdn Trust, London, England

[25] Univ Calif San Diego, Dept Psychiat, San Diego, CA USA

来源：

JOURNAL OF AFFECTIVE DISORDERS | 2025年 / 372卷

基金：

英国医学研究理事会; 英国惠康基金;

关键词：

Psilocybin; Treatment-resistant depression; Psychedelic experience; Randomized-control trial; Psychedelic; Dose-response; COMP360; PSILOCYBIN; DOUBLE-BLIND; ANXIETY; SCALE;

D O I：

10.1016/j.jad.2024.12.061

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. Methods: For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with psychological support. The resulting psychedelic experience (Five- Dimensional Altered States of Consciousness questionnaire [5D-ASC] and Emotional Breakthrough Inventory EBI]) were measured. These proximal variables and outcome 3 weeks post-administration (change in Mont-gomery-& Aring;sberg Depression Rating Scale [MADRS]) were explored using correlation analysis. Results: The mean intensity of psychedelic effects was dose-related, but distributions of scores for different doses overlapped considerably. Depression response correlated with select aspects of the psychedelic experience overall and for individual doses. At the 25 mg dose, 5D-ASC dimensions Oceanic Boundlessness (Pearson cor-relation coefficient r = 0.508) and Visual Restructuralization (r = 0.516), and EBI (r = 0 & sdot;637) were the variables with the strongest correlation to the Week 3 change from Baseline in MADRS score. Limitations: The existence of correlation does not establish causation and exploratory findings require further replication, preferably in larger independent samples. Conclusions: The intensity of psychedelic experience overlaps widely across doses and mitigates the risk of unblinding to dose. Correlations between psychedelic experience and outcome suggest specificity in psilocybin's mechanism of action. Quality and intensity of psychedelic experience may be a measure of pharmacodynamic effect and reveal an effective dose response phenomenon for single oral doses

引用

页码：523 / 532

页数：10

共 36 条

[1] Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes A Nonrandomized Open-Label Trial [J].

Aaronson, Scott T. ;

van der Vaart, Andrew ;

Miller, Tammy ;

LaPratt, Jeffrey ;

Swartz, Kimberly ;

Shoultz, Audrey ;

Lauterbach, Margo ;

Sackeim, Harold A. ;

Suppes, Trisha .

JAMA PSYCHIATRY, 2024, 81 (06) :555-562

[2]

[Anonymous], 2013, American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, VFifth, DOI DOI 10.1176/APPI.BOOKS.9780890425787

[3] The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms [J].